NONPARTISAN · SOURCED FROM CONGRESS.GOV, OPENFEC, SENATE & HOUSE CLERKS · UPDATED REGULARLY
119th Congress · Senate bill · Last action Mar 18, 2026
BillsArmed Forces and National SecurityS. 2807Congress.gov ↗
S. 2807IntroducedArmed Forces and National Security

I don't have access to the bill text for S. 2807 to determine what it does. Since I cannot access the content to write an accurate plain English headline, I must return the official title:RESPECT Act of 2025

Sponsor: Sen. Cornyn, John (R-TX)5 cosponsorsIntroduced Sep 16, 2025
In plain English

A plain-English summary isn’t available for this bill yet.

Where it is in the process

Introduced
Sep 16
Senate committee
Mar 18
3
Senate floor
-
4
House
-
5
Signed
-
What happens next: Awaiting committee assignment or hearings in the Senate.

Sponsor

Cosponsors (5)

MS
LS
JS
RS
AS
3 Democrats, 2 Republicans (of 5 shown).

Activity timeline

Mar 18
Mar 18
Committee on Veterans' Affairs. Ordered to be reported with an amendment in the nature of a substitute favorably.
Dec 10
Dec 10, 2025
Committee on Veterans' Affairs. Hearings held. Hearings printed: S.Hrg. 119-247.
Sep 16
Sep 16, 2025
Read twice and referred to the Committee on Veterans' Affairs.
Sep 16
Sep 16, 2025
Introduced in Senate
Read the bill text
Official text via Congress.gov. Opens in a new tab.
Read full text →

Full action log

All 4 recorded actions since introduction · Source: Congress.gov
2026
Mar 18
SENATECommittee on Veterans' Affairs. Ordered to be reported with an amendment in the nature of a substitute favorably.
2025
Dec 10
SENATECommittee on Veterans' Affairs. Hearings held. Hearings printed: S.Hrg. 119-247.
Sep 16
SENATERead twice and referred to the Committee on Veterans' Affairs.
Sep 16
Introduced in Senate

All 5 cosponsors

3 Democrats · 2 Republicans
Democrats (3)
Republicans (2)

In the news

Senator John Cornyn has filed a new financial disclosure - here’s what we see - Quiver Quantitative
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomise - The Lancet
Denon AVR-2807 review: Denon AVR-2807 - CNET
Track this bill
Get an alert when it moves to the next stage or gets a vote.
Share
Embed this tracker on your site
Paste this HTML into your blog post or website to show a live tracker for this bill.
The embedded card updates automatically as the bill progresses. Preview →